Celebrating the success of the MenAfriVac vaccine
For generations, epidemics of meningitis have swept across 26 countries in sub-Saharan Africa, killing and disabling young people. In response to a plea for help from African ministers of health, the World Health Organization and PATH partnered in 2001 to develop an affordable, tailor-made vaccine for use in sub-Saharan Africa.
The MenAfriVac® vaccine was developed and approved in record time and at less than one-tenth the cost of a typical new vaccine. Introduced in 2010, this new vaccine against meningitis A—the dominant strain at the time—has resulted in one of the biggest immunization success stories in sub-Saharan Africa—near elimination of a deadly infectious disease.
MenAfriVac is a registered trademark of Serum Institute of India Private Ltd.